Postmenopausal Hormone Therapy and Systemic Lupus Erythematosus

Buyon, Jill P.; Belmont, H. Michael; Kalunian, Kenneth C.

doi:10.7326/0003-4819-123-12-199512150-00015

Cited by 7 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some clinical studies have described a link between oestrogen and disease flares, [50][51][52][53][54][55] but others failed to show a correlation. [56][57][58][59][60][61] Two large retrospective surveys suggested that the use of exogenous oestrogen increases the risk of developing SLE: hormone replacement therapy (HRT) with a relative risk of 2.1 62 and oral contraception (OCP) with a relative risk of 1.9. 63 To investigate prospectively the safety of exogenous oestrogen therapies, HRT and OCP, studies termed 'Safety of Estrogens in Lupus Erythematosus: National Assessment' (SELENA) was initiated and showed that HRT increases the number of mild and moderate flares, 64 whereas OCP does not.…”

Section: Consequences For Clinical Considerationmentioning

confidence: 99%

Hormonal regulation of B-cell function and systemic lupus erythematosus

Jeganathan

Hill

et al. 2008

Lupus

View full text Add to dashboard Cite

The prevalence of systemic lupus erythematosus (SLE) is far higher in females than in males and numerous investigations to understand this gender bias have been performed, which propose as casual actors genetic predispositions and sex hormones effects. We will describe in this review how the sex hormones estrogen and prolactin influence B cell maturation and selection, permitting B cells to mature to immunocompetence in a mouse model of lupus. Finally, we will discuss the relevance and implications of these results for human disease.

show abstract